Pharmaceutics/Drug Delivery Grants

Therapeutics Development Initiative 2009
Pre-Proposal Receipt Date: January 20, 2009 – 6:00pm US ET

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the launch of its Therapeutics Development Initiative (TDI) for Spring 2009, a funding mechanism to support and stimulate preclinical Parkinson’s disease research at for-profit institutions. This funding program seeks to support preclinical development of Parkinson’s disease therapies which have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing.
Responsibility for the planning, direction, and execution of the proposed project will be solely that of the principal investigator who must be an employee of a for-profit entity. Academic investigators may have an advisory role in the project, but the operational and strategic ownership of the project must reside within the company.

Investigators may seek up to two years of funding for preclinical development and testing of novel therapeutic approaches for the treatment or prevention of Parkinson’s disease.

Please note that pre-proposals are mandatory and will be used to evaluate your proposal’s fit with the stated aims and review criteria of the RFP. All pre-proposals received in response to this program will be subjected to a triage process and only those pre-proposals deemed to be of suitable scientific merit will be invited to submit a full application.

MJFF employs an expedited, abbreviated granting mechanism to accelerate discoveries and ultimately translate findings to PD patients more quickly.

Conference Call
MJFF will hold a 45 minute long conference call on December 16, 2008 at 12:00 PM U.S. Eastern Time to clarify and explain the Therapeutics Development Initiative 2009 program and to answer applicants' questions. To participate in this call, you must RSVP via email to conferencecalls@michaeljfox.org. Participants will receive a reply with call-in details.

While there are no restrictions as to the specific approaches to be studied under this RFP,
successful applications are most likely to focus on at least one of the following categories:
o Neuroprotective strategies focused on slowing or preventing the process of neuronal
death.
o Neuroregenerative strategies to restore or replace neuronal function.
o Novel drug delivery mechanisms and/or surgical procedures.
o Innovative therapeutic approaches to treat the motor and non-motor symptoms of PD,
including cognitive dysfunction, autonomic dysfunction, sleep disorders, or depression
among others.
o Therapeutic approaches to alleviate complications of PD treatment including dyskinesias,
etc.

If you would like to contact the Foundation, please call toll-free at 1-800-708-7644, or contact us by regular mail at the following address:

The Michael J. Fox Foundation for Parkinson's Research
Church Street Station
P.O. Box 780
New York, NY 10008-0780

American Association of Diabetes Educators Request for Proposals for Building the Evidence: Problem Solving – Injections

The AADE Education and Research Foundation is offering a $40,000 grant for a research project in the field of diabetes education. The Principal Investigator must be an AADE member at the time of application; team members can be from a variety of disciplines.

We are seeking proposals that address problem solving issues and potential solutions surrounding effective insulin/medication injection in patients with a BMI>35 or very low body fat. The overall aim is to identify best practices and effective problem solving solutions for populations who have difficulty with administration of their injections.

Proposals must be postmarked by the first business day of November (Monday, November 3, 2008)

Specific Aims
Currently, there is a lack of research on problem solving issues and potential solutions surrounding
effective insulin/medication injection in patients with a BMI>35 or very low body fat. The overall aim is to
identify best practices and effective problem solving solutions for populations who have difficulty with
administration of their injections. The proposed research must examine the problems that individuals at
both the high and low ends of the BMI Index face regarding injection of insulin or other diabetes
medication with a syringe or insulin pen. The findings will be sufficiently robust that they can be
disseminated to diabetes educators via a presentation and/or publication.
The Researcher will describe in detail the problem solving and injection intervention(s) that will be used,
which method of data collection and analysis will be appropriate for the study, suggested methods for
data collection and analysis follow. The proposed study should also address potential issues, such as
inability of patient to see the injection site due to excess abdominal fat and inability to locate an
appropriate injection site due to low body fat. Once the problems have been identified and documented,
the researchers should implement and evaluate one or more problem solving interventions.
Research questions
1. What are the knowledge, skills and problem solving behaviors that people with diabetes need to
effectively self-manage their injections?
2. What injection techniques should health care professionals use to educate patients to insure that either
obese (BMI >35), extremely thin (BMI <18.5 or extremely muscular) effectively inject insulin or other
diabetes medications once they leave the clinical setting?
3. What problem solving questions or activities can the CDE employ to ensure that the proper technique
is used and/or adjustments to technique are made for the target populations?
This proposal must address these research questions, specific research aims, and state the
intended objectives of the proposed study. Applicants must state the rationale for their
approach to the problem and state the hypothesis this research is designed to address.
Significance
Briefly describe the background information relevant to this proposal, including a brief evaluation
of the existing body of knowledge about the problem. Identify the importance of this study to the
field of diabetes education and/or diabetes nursing practice.

http://www.diabeteseducator.org/Foundation/Grants/CurrentGrants.html

THE BERNARD B. BRODIE AWARD IN DRUG METABOLISM FOR 2010
(Deadline for submission of nominations is September 15, 2009)

The B. B. Brodie Award in Drug Metabolism has been established to honor the fundamental contributions of Bernard B. Brodie in the field of drug metabolism and disposition. The Award is presented biennially in even years to recognize outstanding original research contributions in drug metabolism and disposition, particularly those having a major impact on future research in the field. The B. B. Brodie Award is sponsored by the American Society for Pharmacology and Experimental Therapeutics (ASPET) Division for Drug Metabolism, and funds to support the award come from members’ contributions.

The award consists of a $2,000 honorarium, a commemorative medal, hotel and economy airfare to the award ceremony at the annual meeting. A lecture, delivered by the awardee at the annual meeting, describing appropriate research accomplishments and their future direction, will be published in Drug Metabolism and Disposition.

There are no restrictions on institutional affiliation, and a candidate need not be a member of the Society. The only restriction for the Award is that supporting research accomplishments must not be used to win any other major award. Only one nominator is necessary, although more are acceptable, and the nominators need not be members of ASPET. Selection of an awardee will be made biennially by the B.B. Brodie Award Committee, appointed by the President of ASPET with input from the Division for Drug Metabolism.

Nominations shall be submitted electronically to markin@aspet.org and shall consist of:

Nominating letter and no more than five supporting letters detailing accomplishments of the nominee.

List of, and comments on, the outstanding papers.

Brief biographical sketch of the candidate.

Candidate’s curriculum vitae and bibliography.

Receipt date for nominations for the Bernard B. Brodie Award will be 5:00 pm on September 15, 2009 for an award to be presented at Experimental Biology ’10 in Anaheim, CA.

ADA-ASP Young Investigator Innovation Award in Geriatric Endocrinology
Award Description: The American Diabetes Association (ADA)-Association of Subspecialty Professors (ASP) Young Investigator Innovation Award in Geriatric Endocrinology provides grant support to new investigators. This program supports entry-level faculty to integrate geriatrics with novel basic, clinical, or health services diabetes research. This award supports pilot and feasibility studies that may lack preliminary data, but offer considerable promise for the cure, prevention, or treatment of diabetes in an aging population.
Support: Awards are a maximum of $75,000 per year for up to two years. No indirect costs may be requested.
Deadline Dates: July 15, 2008 for January 1, 2009 funding and January 15, 2009 for July 1, 2009 funding.

Call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383). Our hours of operation are Monday - Friday, 8:30 AM - 8 PM Eastern Standard Time.
Or write to us:
American Diabetes Association
ATTN: National Call Center
1701 North Beauregard Street
Alexandria, VA 22311

American Diabetes Association-Takeda Beta Cell in Diabetes Postdoctoral Fellowship Award
Award Description: These awards, funded by Takeda Pharmaceuticals North America, Inc., are granted to established diabetes investigators to support the training of scientists in an environment most conducive to beginning a career in diabetes research and beta cell biology.
Support: Awards are $45,000 a year for up to two years. No indirect costs may be requested.
Deadline Dates: January 15, 2009 for July 1, 2009 funding. Please note: Funding is not available for this award in 2008.

Call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383). Our hours of operation are Monday - Friday, 8:30 AM - 8 PM Eastern Standard Time.
Or write to us:
American Diabetes Association
ATTN: National Call Center
1701 North Beauregard Street
Alexandria, VA 22311

American Diabetes Association-Takeda Pharmaceuticals Cardiovascular Complications in Diabetes Postdoctoral Fellowship Award
Award Description: These awards, funded by Takeda Pharmaceuticals North America, Inc., are granted to established diabetes investigators to support a postdoctoral fellow being trained in the area of diabetes and cardiovascular disease.
Support: Awards are $45,000 a year for up to two years. No indirect costs may be requested.
Deadline Dates: January 15, 2009 for July 1, 2009 funding. Please note: January funding is not currently for this award.

Call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383). Our hours of operation are Monday - Friday, 8:30 AM - 8 PM Eastern Standard Time.
Or write to us:
American Diabetes Association
ATTN: National Call Center
1701 North Beauregard Street
Alexandria, VA 22311